SC 13D/A

                     SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C. 20549

                                SCHEDULE 13D
                               (Rule 13d-101)

          INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
         TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
                               RULE 13d-2(a)

                              Amendment No. 26


                             Circon Corporation
                              (Name of Issuer)

                  Common Stock, Par Value $0.01 Per Share
                       (Title of Class of Securities)

                                172736 10 0
                               (CUSIP Number)


         Thomas R. Bremer                 Paul T. Schnell, Esq.
       USS Acquisition Corp.              Skadden, Arps, Slate,
    c/o United States Surgical              Meagher & Flom LLP
            Corporation                      919 Third Avenue
         150 Glover Avenue                  New York, NY 10022
         Norwalk, CT 06856                    (212) 735-3000
          (203) 845-1000

               (Name, Address and Telephone Number of Person
             Authorized to Receive Notices and Communications)

                             September 15, 1998

          (Date of Event which Requires Filing of this Statement)


      If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check
the following: ( )



      United States Surgical Corporation, a Delaware corporation
("Parent"), and USS Acquisition Corp., a Delaware corporation (the
"Purchaser") and a wholly owned subsidiary of Parent, hereby further amend
and supplement their Statement on Schedule 13-D (the "Schedule 13D")
originally filed with the Securities and Exchange Commission (the
"Commission") on August 2, 1996, as amended. The item numbers and responses
thereto below are in accordance with the requirements of Schedule 13-D.

      Unless otherwise indicated herein, each capitalized term used but not
defined herein shall have the meaning assigned to such term in the Schedule
13D.


ITEM 4.     PURPOSE OF TRANSACTION.

      Item 4 is hereby supplemented as follows:

            The Offer expired in accordance with its terms on September 15,
1998 and Parent and the Purchaser have terminated the Offer. On September
15, 1998, Parent issued a press release announcing the results of the
Offer, a copy of which is attached hereto as Exhibit (a)(26) and is
incorporated herein by reference. Pending consummation of Parent's
previously announced merger with Tyco, Parent and the Purchaser intend to
review their investment in the Company on a continuing basis and reserve
the right to maintain their holdings at current levels, to sell all or a
portion of their holdings in the open market or in privately negotiated
transactions or otherwise, to acquire additional Shares in the open market
or in privately negotiated transactions or otherwise, or to take such other
actions with respect to their investment in the Company as Parent deems
advisable. Any such actions will depend upon, among other things, the
continuing evaluation of the Company's business, financial condition,
operations and prospects; the trading price of the Company's Common Stock;
general market, economic and other conditions; the relative attractiveness
of alternative business and investment opportunities; the actions of the
management and Board of Directors of the Company; and other future
developments.

ITEM 7.  MATERIAL TO BE FILED AS EXHIBITS.

      Item 7 of the Schedule 13D is hereby amended and supplemented by the
following:

      (a)(26)     Press Release.


                                 SIGNATURE

      After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete and correct.

Dated:  September 16, 1998

                                       USS ACQUISITION CORP.


                                       By: /s/ THOMAS R. BREMER
                                           ___________________________
                                           Name:  Thomas R. Bremer
                                           Title: President


                                       UNITED STATES SURGICAL
                                       CORPORATION


                                       By: /s/ THOMAS R. BREMER
                                           __________________________
                                           Name:  Thomas R. Bremer
                                           Title: Senior Vice President
                                                  and General Counsel



                               EXHIBIT INDEX


EXHIBIT           EXHIBIT NAME

(a)(26)           Press Release.

EX-99

                                                            Exhibit (a)(26)


       FOR IMMEDIATE RELEASE: September 15, 1998


INVESTOR CONTACT:             U.S. SURGICAL HOME PAGE    MEDIA CONTACT:
Marianne Scipione             http://www.ussurg.com      Steve Rose
Vice President                                           Director
Corporate Communications                                 Media Relations
(203) 845-1404                                           (203) 845-1732
marianne.scipione@ussurg.com
steve.rose@ussurg.com


               UNITED STATES SURGICAL CORPORATION TERMINATES
                          TENDER OFFER FOR CIRCON



      NORWALK, Conn. -- United States Surgical Corporation (NYSE:USS)
announced today that its tender offer for Circon Corporation (Nasdaq:CCON)
had expired and that it had terminated the offer.

      Leon C. Hirsch, chairman of USS, said, "In light of USS's proposed
merger with Tyco International Ltd. (NYSE:TYC) and Circon's recent
announcement that it has invited various companies to make bids to acquire
Circon, USS has determined not to continue its offer."

      USS has instructed the depositary for the offer to promptly return
all Circon shares tendered in the offer to Circon stockholders. Questions
regarding tendered shares can be directed to USS's information agent,
Kissel-Blake Inc., at 212-344-6733.

      As of 6:00 p.m., New York City time, on September 15, 1998, 6,356,259
shares of Circon's outstanding common stock had been tendered to USS under
the terms of the offer.

      United States Surgical Corporation is a diversified medical products
company specializing in minimally invasive technologies that improve
patient care and lower health care costs.